NCT04517838
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 8 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Insufficient funding to complete target accrual Show 5 more changesShow less
- Eligibility criteria expanded, about 9 words
- Final enrollment: 127 participants (planned 230)
- Primary completion date changed from estimate of Jul 27, 2028 to Jan 15, 2026
- Study description revised
- Site details revised
- Notable Primary completion date: Jul 27, 2027 to Jul 27, 2028v11
- Notable Enrollment target: 750 to 230
- Site contact updated
- Minor Start date: Jul 27, 2020 to Jul 31, 2020
- Site contact updated
Notable Enrollment target: 500 to 750v6 Show 4 more changesShow less
- Primary endpoints revised (2)
- Eligibility criteria shortened, about 1 word
- Study description expanded, about 83 words
- Study arms: 1 to 2
Show 2 earlier versionsHide 2 earlier versions
- Notable Eligibility criteria expanded, about 4 words
- Collaborators shortened, about 4 words
- Minor Study description expanded, about 51 words
- Site contact updated
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Patients with stage I-III disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. Patients with stage IV disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of progressive disease. Patients with stage IV disease with no disease progression ≥ 2 years on the same line of therapy undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. For all patients, tissue samples from previous biopsy and/or surgical resection are also collected on study.
For patients with stage I-IV disease who received or previously completed anti-HER2 therapy, tissue samples from previous biopsy and/or surgical resection are collected on study.
Procedures: Biospecimen Collection
Sites
1 site in 1 country
- Mayo Clinic in FloridaJacksonville, Florida, United States